基本説明
Part 1 describes the basic mechanisms. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.
Full Description
Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases.
